ClinicalTrials.gg
CompletedNCT01874457Updated Jun 17, 2013

Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella)

An observational study in Mumps, Rubella and Measles, sponsored by The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz). Completed at 1 site in Brazil. Open to participants aged 12 Months to 24 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-06-17.

Sponsored by The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) · Observational

Study type
Observational
Time perspective
Prospective
Enrollment
150
Ages
12 Months to 24 Months
Sex
All
01

Study summary

On a previous study conducted in Brazil. The MMR vaccine from 2 different producers had a mumps seroconversion much lower (71%) than the expected 95%, according to the package insert. This could indicate that a substantial proportion of children was not protected after MMR dose.

Read the detailed description

Given the above and considering: (1) future clinical study with the MMR vaccine produced entirely in Bio-Manguinhos/Fiocruz from technology transfer from GlaxoSmithKline (GSK), (2) the importance to the National Immunization Program (NIP) to provide the population a MMR vaccine to ensure high protection against mumps, similar to what occurs with measles and rubella components, it was considered essential to conduct a preliminary immunogenicity assessment of the MMR vaccine produced by BioManguinhos.

02

Conditions studied

  • Mumps
  • Rubella
  • Measles
03

In context

Mumps

83 studies on the registry are indexed under Mumps; 8 are open to participants now.

This study's enrollment of 150 is below the median of 600 across 11 observational studies indexed under Mumps.

Browse Mumps studies →

Lead sponsor

The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) is the lead sponsor of 28 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Months to 24 Months
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Children 12-23 months and 29 days old, in the routine of PNI in health units in the city of Rio de Janeiro.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children of both sexes;
  • Age between 12 months to 23 months and 29 days;
  • Child in good health, with no significant past medical history;
  • Have completed blood sampling before vaccination;
  • Have not been vaccinated with MMR.
  • Agreement by parents/tutors with the child's participation in the study and signing of the Form (ICF);
  • Parents/Tutors provide name, address, telephone number and other information for the contact if necessary;
  • Parents/Tutors able to understand the risks of the experiment, although minimal;
  • Parents/Tutors able to understand and sign the informed consent form.
  • Availability of return for collecting post-vaccination samples.

Exclusion criteria

Exclusion criteria:

  • Children with a history of measles, rubella and / or mumps.
  • Having received MMR vaccine previously, as documented in vaccination card.
  • Having received a transfusion of blood or blood products, including immunoglobulins, within last 12 months.
  • Skin lesions at sites of venipuncture.
  • Child subject to abnormal bleeding after injections.
  • Use within 6 months of (excluding topical or aerosol) and .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Time perspective
Prospective
Enrollment
150 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • BiologicalMMR (Mumps, Measles and Rubella)

    MMR (Mumps, Measles and Rubella)

06

What researchers measure

Primary outcomes

  1. Immunoresponse after first dose

    Assess the immunoresponse for measles, mumps and rubella after vaccination with MMR in children 12-23 months and 29 days old, in the routine of National Immunization Program (NIP) in health units in the city of Rio de Janeiro.

    Time frame: 42 days

Secondary outcomes

  1. Immunoresponse after revaccination

    To evaluate the immunoresponse after revaccination of children who did not seroconvert for any of the three components of the vaccine.

    Time frame: 42 days

07

Study locations

1 site
  • Bio-Manguinhos/Fiocruz
    Rio de Janeiro, 21040-360, Brazil
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Mar 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2013
First posted
Jun 11, 2013
Start
May 2008
Primary completionActual
Mar 2009
CompletionActual
Aug 2009
Last update
Jun 17, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01874457
Lead sponsor
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Responsible party
Sponsor
First posted
Jun 11, 2013
Start date
May 2008
Primary completion
Mar 2009
Completion
Aug 2009
Last update
Jun 17, 2013

Study contacts

Glória Regina da Silva e Sá, Doctorate
principal investigator · Immunobiological Technology Institute (Bio-Manguinhos)

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion